Trading Report: The Vetr Inc. Upgrades Alexion Pharmaceuticals Inc. (ALXN) to Sell

The Vetr Inc. Upgrades Alexion Pharmaceuticals Inc. (ALXN) to Sell

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was upgraded by Vetr from a “strong sell” rating to a “sell” rating in a report issued on Monday. The firm currently has a $131.00 price objective on the biopharmaceutical company’s stock. Vetr‘s price objective would suggest a potential downside of 3.39% from the company’s previous close.

A number of other equities research analysts have also recently commented on ALXN. Piper Jaffray Cos. reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Thursday, July 7th. Leerink Swann reissued a “buy” rating and issued a $200.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 8th. Credit Suisse Group AG raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Saturday, July 9th. Royal Bank Of Canada assumed coverage on shares of Alexion Pharmaceuticals in a research note on Tuesday, July 12th. They issued an “outperform” rating and a $188.00 price objective on the stock. Finally, SunTrust Banks Inc. decreased their price target on shares of Alexion Pharmaceuticals from $220.00 to $197.00 and set a “buy” rating on the stock in a research note on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $175.23.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 135.59 on Monday. Alexion Pharmaceuticals has a 52-week low of $110.56 and a 52-week high of $193.45. The firm’s 50-day moving average price is $125.04 and its 200-day moving average price is $132.89. The stock has a market cap of $30.40 billion, a P/E ratio of 82.68 and a beta of 1.33.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.23 EPS for the quarter, beating the Zacks’ consensus estimate of $1.04 by $0.19. The firm had revenue of $799 million for the quarter, compared to analysts’ expectations of $787.07 million. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The firm’s revenue was up 19.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.16 EPS. Equities analysts predict that Alexion Pharmaceuticals will post $4.68 EPS for the current year.

In other news, EVP Julie O’neill sold 650 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Friday, September 2nd. The shares were sold at an average price of $126.29, for a total transaction of $82,088.50. Following the sale, the executive vice president now owns 35,384 shares in the company, valued at $4,468,645.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Carsten Thiel sold 4,584 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Friday, October 14th. The shares were sold at an average price of $120.28, for a total transaction of $551,363.52. Following the sale, the executive vice president now owns 32,741 shares in the company, valued at approximately $3,938,087.48. The disclosure for this sale can be found here. 4.41% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the stock. Meeder Asset Management Inc. purchased a new stake in Alexion Pharmaceuticals during the first quarter worth about $114,000. Cornerstone Advisors Inc. raised its stake in Alexion Pharmaceuticals by 47.4% in the third quarter. Cornerstone Advisors Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 310 shares in the last quarter. NEXT Financial Group Inc raised its stake in Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 440 shares in the last quarter. Bellwether Investment Group LLC purchased a new stake in Alexion Pharmaceuticals during the second quarter worth about $172,000. Finally, Charlemagne Capital Ltd. purchased a new stake in Alexion Pharmaceuticals during the second quarter worth about $191,000. Institutional investors own 96.36% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Related posts

Leave a Comment